Motixafortide dosage in published studies and labels

These are the doses used for Motixafortide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Motixafortide has an FDA-approved human dosage, as Aphexda, used together with filgrastim (G-CSF) to mobilise blood stem cells for collection and autologous transplantation in people with multiple myeloma. The label's recommended dose is 1.25 mg/kg of actual body weight by slow subcutaneous injection 10 to 14 hours before the first apheresis, with a second dose allowed before a third apheresis.

FDA Approved

Dosage evidence summary for Motixafortide
Human dosing established	Yes
Studied dose range	1.25 mg/kg before apheresis (FDA label)
Route	Subcutaneous
Frequency	One dose before the first apheresis; a second dose may be given before a third apheresis
Duration studied	One or two doses per mobilisation
Half-life	Effective half-life about 2 hours
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Motixafortide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Aphexda with filgrastim, stem cell mobilisationFDA-approved label · FDA prescribing information	Adults with multiple myeloma undergoing stem cell collection for autologous transplantation	1.25 mg/kg actual body weight, after filgrastim 10 mcg/kg once daily for 4 days and with premedication	Subcutaneous, slow injection over about 2 minutes	10–14 hours before the first apheresis; a second dose 10–14 hours before a third apheresis if needed	One or two doses	In the GENESIS trial (NCT03246529), 67.5% reached the collection goal of at least 6 million CD34+ cells/kg in up to two aphereses, versus 9.5% with placebo plus filgrastim	APHEXDA (motixafortide) for injection (Gamida Cell) — FDA prescribing information, DailyMed

Where sources disagree

The label requires premedication before every dose (an H1 antihistamine, an H2 blocker and a leukotriene inhibitor, plus an analgesic) and administration where anaphylaxis can be treated: anaphylactic shock occurred in 0.7% of treated patients in clinical studies.
The label warns that it may mobilise leukemic cells and should not be used in people with leukemia, and that it raises white cell counts. Safety and effectiveness in children have not been established.
The label describes a lyophilised powder vial that is reconstituted before injection.